Soleno Therapeutics Inc.
Soleno Therapeutics Reports Second Quarter 2025 Financial Results and Updates on VYKAT XR Launch
Summary
Soleno Therapeutics, Inc. announced its financial results for the second quarter of 2025, reporting a net loss of $4.7 million and net product revenue of $32.7 million. The company launched VYKAT XR, its FDA-approved treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS), on April 14, 2025, with positive initial reception. Soleno also raised $230 million in gross proceeds through a common stock offering in July 2025. Key financial metrics include cost of goods sold of $0.7 million, research and development expenses of $9.1 million, and selling, general and administrative expenses of $28.2 million for the quarter.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement